Malaysia-EU FTA Draws Political Criticism For Impact On Drug Access
This article was originally published in PharmAsia News
Executive Summary
Concerns have been raised by members of parliament in Malaysia that a proposed Free Trade Agreement with the European Union may limit drug access in the Malaysian market. Malaysia and the EU are currently negotiating an FTA and are expected to meet in June for a second round of meetings, and the agenda includes discussion of a clause to extend the patent life for innovative medicines
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)
Need a specific report? 1000+ reports available
Buy Reports